Prednisone in uric acid lowering in symptomatic heart failure patients with hyperuricemia (PUSH-PATH) study

Canadian Journal of Cardiology

Volumn 29, Issue 9, 2013, Pages 1048-1054

  Liu, Chao ^a   Zhao, Qingzhen ^a   Zhen, Yuzhi ^a   Gao, Yanqiu ^a   Tian, Li ^a   Wang, Le ^a   Ji, Lishuang ^a   Liu, Gang ^a   Ji, Zhenguo ^a   Liu, Kunshen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; FUROSEMIDE; PREDNISONE; URIC ACID;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY WEIGHT; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DIURESIS; DIURETIC THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH STATUS; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPOKALEMIA; KIDNEY FUNCTION; MALE; NEW YORK HEART ASSOCIATION CLASS; OPEN STUDY; PARALLEL DESIGN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; URIC ACID BLOOD LEVEL; URINE VOLUME; XEROSTOMIA;

ADULT; ALLOPURINOL; CREATININE; DYSPNEA; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOCORTICOIDS; GOUT SUPPRESSANTS; HEART FAILURE; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDNISONE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URIC ACID;

EID: 84882860481     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.11.008     Document Type: Article

References (26)

1. Tian Y., Chen Y., Deng B., et al. Serum uric acid as an index of impaired renal function in congestive heart failure. JGeriatr Cardiol 2012, 9:137-142.
2. Dzudie A., Kengne A.P., Mbahe S., Menanga A., Kenfack M., Kingue S. Chronic heart failure, selected risk factors and co-morbidities among adults treated for hypertension in a cardiac referral hospital in Cameroon. Eur J Heart Fail 2008, 10:367-372.
3. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10:933-989.
4. Erdogan D., Tayyar S., Uysal B.A., et al. Effects of allopurinol on coronary microvascular and left ventricular function in patients with idiopathic dilated cardiomyopathy. Can J Cardiol 2012, 28:721-727.
5. Hare J.M., Mangal B., Brown J., et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. JAm Coll Cardiol 2008, 51:2301-2309.
6. Spieker L.E., Ruschitzka F.T., Luscher T.F., Noll G. The management of hyperuricemia and gout in patients with heart failure. Eur J Heart Fail 2002, 4:403-410.
7. Liu C., Chen Y., Kang Y., et al. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-a expression in the renal inner medullary collecting duct in decompensated heart failure. JPharmacol Exp Ther 2011, 339:203-209.
8. Massari F., Mastropasqua F., Iacoviello M., Nuzzolese V., Torres D., Parrinello G. The glucocorticoid in acute decompensated heart failure: DrJekyll or Mr Hyde?. Am J Emerg Med 2012, 30. 517.e5-10.
9. Liu C., Liu G., Zhou C., Ji Z., Zhen Y., Liu K. Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance. Can J Cardiol 2007, 23:865-868.
10. Liu C., Chen H., Zhou C., et al. Potent potentiating diuretic effects of prednisone in congestive heart failure. JCardiovasc Pharmacol 2006, 48:173-176.
11. Janssens H.J., Janssen M., van de Lisdonk E.H., van Riel P.L., van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008, 371:1854-1860.
12. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. Amore accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
13. Sorensen L.B., Levinson D.J. Origin and extrarenal elimination of uric acid in man. Nephron 1975, 14:7-20.
14. Wu A.H., Ghali J.K., Neuberg G.W., O'Connor C.M., Carson P.E., Levy W.C. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J 2010, 160:928-933.
15. Mullens W., Abrahams Z., Francis G.S., et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. JAm Coll Cardiol 2009, 53:589-596.
16. Zhang H., Liu C., Ji Z., et al. Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. Int Heart J 2008, 49:587-595.
17. Liu C., Guan J., Kang Y., et al. Inhibition of dehydration-induced water intake by glucocorticoids is associated with activation of hypothalamic natriuretic peptide receptor-A in rat. PLoS One 2010, 5:e15607.
18. Antunes-Rodrigues J., de Castro M., Elias L.L., Valenca M.M., McCann S.M. Neuroendocrine control of body fluid metabolism. Physiol Rev 2004, 84:169-208.
19. Bryan P.M., Xu X., Dickey D.M., Chen Y., Potter L.R. Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations. Am J Physiol Renal Physiol 2007, 292:F1636-1644.
20. Damjancic P., Vierhapper H. Permissive action of glucocorticoid substitution therapy on the effects of atrial natriuretic peptide (hANP) in patients with adrenocortical insufficiency. Exp Clin Endocrinol 1990, 95:315-321.
21. May C.N., Bednarik J.A. Regional hemodynamic and endocrine effects of aldosterone and cortisol in conscious sheep. Comparison with the effects of corticotropin. Hypertension 1995, 26:294-300.
22. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). JAm Coll Cardiol 1996, 27:1201-1206.
23. Dunlay S.M., Weston S.A., Redfield M.M., Killian J.M., Roger V.L. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation 2008, 118:625-631.
24. Colombo P.C., Ganda A., Lin J., et al. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 2012, 17:177-190.
25. Liu C., Chen J., Liu K. Immunosuppressive treatment for inflammatory cardiomyopathy: meta-analysis of randomized controlled trials. Int Heart J 2005, 46:113-122.
26. Mason J.W., O'Connell J.B., Herskowitz A., et al. Aclinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. NEngl J Med 1995, 333:269-275.